InfoRLife SA v. Sagent Pharmaceuticals

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: InforLife SA (Switzerland); Sintetica S.A. (Switzerland)
  • Defendant: Sagent Pharmaceuticals (Inc.) (Wyoming)
  • Plaintiff's Counsel: Rothwell, Figg, Ernst & Manbeck, P.C.
• Case Identification: 1:25-cv-00387, D. Del., 07/07/2025
• Venue Allegations: Venue is alleged to be proper in the District of Delaware, and the complaint notes that on March 27, 2025, counsel for Defendant Sagent confirmed it will not contest personal jurisdiction or venue for this litigation.
• Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for generic norepinephrine solutions constitutes an act of infringement of three patents related to stable, ready-to-use, injectable pharmaceutical formulations.
• Technical Context: The technology concerns formulations of norepinephrine, a drug used to restore blood pressure, designed to be stable for long-term storage at room temperature without requiring antioxidants, which can carry health risks.
• Key Procedural History: This is a Hatch-Waxman action triggered by Sagent's ANDA filing and its February 14, 2025 notice letter to Plaintiff InforLife, which asserted non-infringement and/or invalidity of the patents-in-suit. The patents are listed in the FDA's "Orange Book" in connection with Plaintiffs' approved norepinephrine products.

Case Timeline

Date	Event
2014-02-27	'RE422 and 'RE443 Patent Priority Date
2019-04-26	'534 Patent Priority Date
2021-01-12	U.S. Patent 10,888,534 Issued
2023-02-21	U.S. Reissue Patent RE49,422 Issued
2023-03-07	U.S. Reissue Patent RE49,443 Issued
2025-02-14	Sagent sends Notice Letter regarding ANDA submission
2025-03-27	Sagent confirms it will not contest jurisdiction or venue
2025-07-07	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,888,534 - "Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags"

• Patent Identification: U.S. Patent No. 10,888,534, "Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags," issued January 12, 2021.

The Invention Explained

• Problem Addressed: The patent's background section explains that conventional norepinephrine solutions are highly concentrated, require dilution before use, and contain antioxidants like sulfites ʻ534 Patent, col. 1:15-32 This process introduces risks of microbial contamination, dilution errors, and adverse health reactions to the antioxidants ʻ534 Patent, col. 1:29-32 ʻ534 Patent, col. 1:45-47 Furthermore, these solutions lack long-term stability at room temperature ʻ534 Patent, col. 1:52-58
• The Patented Solution: The invention is a ready-to-use, antioxidant-free norepinephrine solution that achieves long-term room-temperature stability through a specific packaging system ʻ534 Patent, abstract The solution is placed in a flexible plastic container, which is then sealed inside a low-oxygen-permeability over-wrap pouch that also contains an oxygen absorber ʻ534 Patent, col. 4:11-21 This packaging configuration, illustrated in Figure 1 of the patent, removes oxygen from the environment surrounding the solution, preventing oxidative degradation without the need for chemical antioxidants ʻ534 Patent, col. 4:49-59
• Technical Importance: This approach provides a commercially viable, ready-to-use norepinephrine IV solution that enhances patient safety by eliminating dilution steps and avoiding sulfite-based antioxidants, while also being practical for storage in emergency and intensive care settings.

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶32
• Claim 1 of the '534 Patent requires:
  • A sterile, antioxidant-free aqueous norepinephrine solution packaged in a flexible plastic container in a sealed over-wrap pouch containing an oxygen absorber.
  • The solution consists essentially of specific concentrations of norepinephrine, a tonicity adjusting agent, an acid/optional base to achieve a pH of 3.6-3.8, and water.
  • A negative limitation wherein dissolved oxygen has not been removed from the solution before filling the container.
  • A stability requirement wherein after 12-24 months of room temperature storage, the solution remains clear and colorless and/or retains at least 90% of its initial norepinephrine amount.
• The complaint does not explicitly reserve the right to assert dependent claims but references "one or more claims" Compl. ¶39

U.S. Reissue Patent No. RE49,422 - "Process for producing a stable low concentration, injectable solution of noradrenaline"

• Patent Identification: U.S. Reissue Patent No. RE49,422, "Process for producing a stable low concentration, injectable solution of noradrenaline," issued February 21, 2023.

The Invention Explained

• Problem Addressed: The patent addresses the challenge that noradrenaline (norepinephrine) is easily decomposable when exposed to oxygen, leading to colored by-products and loss of efficacy ʻRE422 Patent, col. 2:18-24 While antioxidants like sulfites can be used, they are associated with allergic reactions ʻRE422 Patent, col. 2:29-34
• The Patented Solution: The patent discloses a process for producing a stable, low-concentration noradrenaline solution that is free of preservatives and antioxidants ʻRE422 Patent, abstract The key process steps include dissolving noradrenaline in "deoxygenated or degassed water," adjusting the pH to a narrow acidic range (3.3 to 3.6), and then filtering and distributing the solution in an inert gas current (e.g., nitrogen) to prevent re-exposure to oxygen ʻRE422 Patent, col. 3:13-23 ʻRE422 Patent, col. 4:20-33
• Technical Importance: This process-focused invention provides a method to create a stable, injectable noradrenaline solution that is inherently free of common preservatives and antioxidants, thereby improving its safety profile for patients.

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 4 Compl. ¶55
• Claim 4 of the 'RE422 Patent requires:
  • A stable injectable noradrenaline solution comprising noradrenaline, a solvent, an excipient (NaCl), and hydrochloric acid.
  • The concentration of noradrenaline is less than or equal to 0.2 mg/ml.
  • The solvent consists of "degassed or deaerated water."
  • The pH is in the range of 3.3 to 3.6.
  • The solution is free of preservatives, anti-oxidizing agents, and complexing agents.
• The complaint references "one or more claims" Compl. ¶65

U.S. Reissue Patent No. RE49,443 - "Process for producing a stable low concentration, injectable solution of noradrenaline"

• Patent Identification: U.S. Reissue Patent No. RE49,443, "Process for producing a stable low concentration, injectable solution of noradrenaline," issued March 7, 2023.
• Technology Synopsis: This patent, similar to the 'RE422 Patent, is directed to a stable, injectable noradrenaline solution that is free of preservatives and anti-oxidizing agents Compl. ¶80 The claimed solution achieves stability through formulation parameters including a specific noradrenaline concentration range (0.04 to 0.2 mg/ml), the use of "degassed or deaerated water" as the solvent, and a pH range of 3.3 to 3.6 Compl. ¶85
• Asserted Claims: The complaint asserts infringement of at least independent claim 1 Compl. ¶84
• Accused Features: The complaint alleges that "at least Sagent's 16 mg/250 ml ANDA Product" infringes the 'RE443 Patent Compl. ¶84

III. The Accused Instrumentality

• Product Identification: The accused instrumentalities are "Sagent's ANDA Products," which are generic versions of norepinephrine bitartrate in 0.9% sodium chloride for intravenous use Compl. ¶1 The complaint identifies three specific concentrations: 4 mg/250 ml, 8 mg/250 ml, and 16 mg/250 ml Compl. ¶20 Compl. ¶30
• Functionality and Market Context: The complaint alleges that Sagent's ANDA Products are generic versions of Plaintiffs' own commercial products and, by virtue of the ANDA filing, are represented to the FDA as having the same active ingredient, dosage form, route of administration, and strength, and as being bioequivalent to Plaintiffs' products Compl. ¶31 Compl. ¶57 The products are catecholamines indicated for restoring blood pressure in adult patients with acute hypotensive states Compl. ¶18 The lawsuit arises under the Hatch-Waxman Act, where the submission of an ANDA seeking approval to market a generic drug before the expiration of listed patents is a statutory act of infringement Compl. ¶1 Compl. ¶37 The complaint references Figure 1 of the '534 Patent, which is attached as Exhibit A, to illustrate the claimed packaging configuration involving an IV solution, a barrier film, and an oxygen absorber Compl. ¶23 '534 Patent, Fig. 1

IV. Analysis of Infringement Allegations

'534 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A sterile, antioxidant-free aqueous norepinephrine solution packaged in a flexible plastic container in a sealed over-wrap pouch containing an oxygen absorber...	Sagent's ANDA Products are alleged to be sterile, antioxidant-free aqueous norepinephrine solutions packaged in flexible plastic containers in sealed over-wrap pouches containing an oxygen absorber.	¶35	col. 4:11-21
...consisting essentially of between about 0.010 and 0.2 mg/ml of norepinephrine concentration as free base,	Sagent's ANDA Products are alleged to meet the claimed concentration range.	¶35	col. 3:60-64
a tonicity adjusting agent to provide an osmolality of from 260 and 320 mosm/kg, and	Sagent's ANDA Products are alleged to contain a tonicity adjusting agent and meet the claimed osmolality.	¶35	col. 3:45-51
sufficient acid and optionally a base to provide a pH of from about 3.6 to 3.8, with the remainder water, and	Sagent's ANDA Products are alleged to be formulated to the claimed pH range.	¶35	col. 4:1-5
wherein dissolved oxygen in the solution has not been removed before filling the flexible plastic container with the solution, and	Sagent's ANDA Products are alleged to be manufactured without a pre-filling deoxygenation step.	¶35	col. 5:39-54
wherein, after storage for from 12 months to about 24 months at room temperature of about 25° C., the solution remains clear and colorless and/or the solution contains 90% or more of an initial amount of norepinephrine.	Sagent's ANDA Products are alleged to meet the claimed long-term stability requirements.	¶35	col. 6:3-10

'RE422 Patent Infringement Allegations

Claim Element (from Independent Claim 4)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A stable injectable noradrenaline solution comprising noradrenaline or a pharmaceutically acceptable salt thereof, a solvent, an excipient, and hydrochloric acid...	Sagent's ANDA Products are alleged to be stable injectable noradrenaline solutions containing the claimed components.	¶61	col. 3:45-49
...wherein the concentration of noradrenaline...is less than or equal to 0.2 mg/ml,	Sagent's ANDA Products are alleged to have a noradrenaline concentration within the claimed range.	¶61	col. 4:57-59
the solvent consists of degassed or deaerated water,	Sagent's ANDA Products are alleged to be made with degassed or deaerated water as the solvent.	¶61	col. 4:40-43
the excipient is NaCl, and	Sagent's ANDA Products are alleged to contain sodium chloride as an excipient.	¶61	col. 6:8-11
the pH of the solution is in the range of 3.3 to 3.6, and	Sagent's ANDA Products are alleged to have a pH within the claimed range.	¶61	col. 5:5-11
wherein the solution is free of preservatives and anti-oxidizing agents and complexing agents.	Sagent's ANDA Products are alleged to be free of preservatives, antioxidants, and complexing agents.	¶61	col. 3:3-8

• Identified Points of Contention:
  • Process Contradiction: A potential conflict exists between the asserted patents. The '534 Patent explicitly claims a solution where "dissolved oxygen...has not been removed before filling" ʻ534 Patent, cl. 1, whereas the 'RE422 Patent claims a solution where the "solvent consists of degassed or deaerated water" ʻRE422 Patent, cl. 4 The litigation may focus on whether Sagent's single manufacturing process, as detailed in its ANDA, can simultaneously infringe both of these seemingly contradictory limitations.
  • Stability Evidence: Infringement of the '534 Patent's stability limitation (stable for 12-24 months) in an ANDA case raises an evidentiary question. The analysis will depend on the stability data and representations Sagent made to the FDA in its confidential ANDA submission, as the filing itself is the act of infringement.
  • Product-by-Process Scope: The 'RE422 Patent claims a product defined in part by its manufacturing process (e.g., use of "degassed or deaerated water"). A key factual dispute will likely be whether Sagent's manufacturing process, which is not public, meets this limitation. The complaint alleges this "upon information and belief," which is standard but signals a point for discovery and contention.

V. Key Claim Terms for Construction

For the '534 Patent:

• The Term: "consisting essentially of"
• Context and Importance: This transitional phrase is narrower than "comprising" and broader than "consisting of." Its construction will be critical to determining whether any unlisted ingredients in Sagent's ANDA Products are permissible. Practitioners may focus on this term because the dispute will turn on whether any additional components in Sagent's formulation materially alter the "basic and novel properties" of the invention, which the patent identifies as long-term, room-temperature stability in an antioxidant-free solution.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not explicitly forbid all other components. A party could argue that only unlisted ingredients that actively interfere with the stability or antioxidant-free nature of the solution are excluded.
  • Evidence for a Narrower Interpretation: The specification emphasizes the desirability of avoiding not only antioxidants but also sugars to prevent hyperglycemia ʻ534 Patent, col. 1:39-44 ʻ534 Patent, col. 2:1-4 This may support an interpretation that the "basic and novel properties" are sensitive, and thus the claim scope is narrow, excluding many types of additional agents.

For the 'RE422 Patent:

• The Term: "degassed or deaerated water"
• Context and Importance: This term is fundamental to the 'RE422 Patent's strategy for achieving stability without antioxidants. The central question for claim construction will be how much oxygen must be removed for water to qualify as "degassed or deaerated." Practitioners may focus on this term because the infringement analysis will hinge on the specific oxygen levels in the water used in Sagent's manufacturing process.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term itself does not specify a numerical threshold. A party could argue that any process that actively removes a meaningful amount of dissolved gas from the water meets the limitation, without being tied to a specific parts-per-billion (ppb) level.
  • Evidence for a Narrower Interpretation: The specification provides a quantitative example, stating that upon completion of the dissolving step, the solution has a "residual oxygen content equal to or lower than 100 ppb" ʻRE422 Patent, col. 4:60-62 A party may argue that this figure defines the required level of deoxygenation for the claimed term.

VI. Other Allegations

• Indirect Infringement: The complaint alleges Sagent will actively induce infringement upon FDA approval. The basis for this allegation is that Sagent's proposed product labeling will instruct healthcare professionals to administer the ANDA products, which allegedly constitutes a direct infringement of the claims Compl. ¶41 Compl. ¶67 Compl. ¶93
• Willful Infringement: The complaint alleges that Sagent acted with full knowledge of the patents-in-suit. Knowledge of the '534 Patent is alleged based on Sagent's Notice Letter Compl. ¶41 Knowledge of the 'RE422 and 'RE443 Patents is alleged based on their listing in the FDA's Orange Book Compl. ¶67 Compl. ¶93 The complaint further alleges that Sagent has acted "without a reasonable basis for believing that it would not be liable for infringement," which forms the basis for a willfulness claim Compl. ¶44 Compl. ¶70 Compl. ¶96

VII. Analyst's Conclusion: Key Questions for the Case

1. Manufacturing Process Contradiction: A primary issue will be whether Sagent's manufacturing process can infringe both the '534 Patent, which requires that dissolved oxygen not be removed from the solution prior to packaging, and the 'RE422 and 'RE443 Patents, which require the use of "degassed or deaerated water." The resolution will depend on the factual details of Sagent's process and the court's construction of these conflicting claim limitations.

2. Evidentiary Sufficiency of the ANDA Filing: A key evidentiary question will be one of conformance to claimed properties: do the confidential materials in Sagent's ANDA submission contain data or representations sufficient to prove, by a preponderance of the evidence, that its proposed commercial product will meet all claim limitations? This is particularly relevant for the long-term stability and purity requirements of the '534 patent.

3. Definitional Scope of Formulation Terms: The case will likely turn on a battle of definitional scope during claim construction. The court's interpretation of "consisting essentially of" in the '534 patent will determine which, if any, unlisted excipients are permitted in the accused product, while the definition of "degassed or deaerated water" in the reissue patents will set the threshold for the oxygen level required by the claims.